Liposuction Isn’t Weight Loss: Understanding What the Procedure Actually Does

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Cosmetic procedures are becoming more popular each year, with the International Society of Aesthetic Plastic Surgery reporting a 40% increase in such treatments since 2020.1 While many types of procedures are available to modern patients, liposuction has remained among the most popular for decades. However the purpose of the surgery is still often misunderstood. Many […]

The post Liposuction Isn’t Weight Loss: Understanding What the Procedure Actually Does appeared first on Medical News Bulletin.

A Practical Checklist for Choosing a Family Dentist in Everett

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Everett is the county seat and most populous city of Snohomish County, Washington, located only 25 miles north of Seattle. If you’ve been thinking about moving here you should know that you’re not alone. Many people choose to relocate to the city due to its affordable housing costs and the numerous job opportunities attracting both […]

The post A Practical Checklist for Choosing a Family Dentist in Everett appeared first on Medical News Bulletin.

Mediterranean, low-carb or plant-based? Which is best for metabolic health?

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Does macro composition of our diet matter when it comes to metabolic health? Find out which diet led to a 200% upgrade in insulin sensitivity

The post Mediterranean, low-carb or plant-based? Which is best for metabolic health? appeared first on Medical News Bulletin.

Holistic-minded eye care: Shift from reactive to preventative

For most of its modern history, eye care has operated on a reactive model. A patient notices blur, burning or floaters; we examine, diagnose and treat.
The model works, but it has a fundamental limitation: By the time symptoms drive a patient into our chairs, disease processes are often well established. Meibomian glands have atrophied, retinal changes have progressed, and refractive error has accelerated through childhood unchecked.
In this new column, I want to make the case for a different orientation, one I call holistic-minded eye care. It is not about abandoning evidence-based medicine

Cefazolin plus gentamicin, ceftriaxone yield similar outcomes

NASHVILLE, Tenn — Cefazolin plus gentamicin and ceftriaxone may offer similar infection rates for patients with open lower extremity fractures, according to results presented at the Orthopaedic Trauma Association Annual Meeting.
“When considering which antibiotic prophylaxis to give on initial presentation with these injuries, there was no difference in our primary outcome of fracture-related infection between the two regimens,” Cameron Foster, MD, presenter and PGY-4 in the department of orthopedic surgery and rehabilitation at the University of Florida College of Medicine

Real-world wet AMD outcomes improved with aflibercept 8 mg

VIENNA — A 6-month interim analysis of Eylea HD demonstrated stable visual acuity, decreased central retinal thickness, increased retinal drying and no new safety signals.
SPECTRUM is an ongoing, global, phase 4 prospective observational study evaluating the real-world effectiveness and safety of Eylea HD (aflibercept 8 mg, Regeneron/Bayer) in patients with age-related macular degeneration or diabetic macular edema. At the Euretina congress, Marion R. Munk, MD, PhD, presented new outcomes for the neovascular AMD subgroup.
“The pretreated neovascular AMD group included 1,100 patients who had

Oncologists give ambient AI scribes positive reviews

Clinicians in cancer settings report high satisfaction with ambient AI scribes despite minimal improvements in closing notes and after-hours electronic health record work.
A prospective survey evaluating an AI scribe at Memorial Sloan Kettering Cancer Center and presented at ASCO Quality Care Symposium showed “lower than expected” uptake, but approximately three-quarters of respondents noted they would recommend the tool to others, Abigail Baldwin-Medsker, MBA, MSN, RN, senior director of quality optimization and innovation at Memorial Sloan Kettering Cancer Center, told Healio.
“We want our

Millions at risk for drug-resistant infections, CDC says

Federal data published Tuesday showed an increase in infections and deaths related to drug resistance in the United States since the last time the CDC issued a report on the subject years ago.
Overall infections caused by antimicrobial-resistant pathogens climbed to almost 10 million in 2023 and deaths surpassed 50,000, the CDC reported — although it noted that some of the increase may be related to changes in surveillance.
“Antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year,” CDC Director Erica Schwartz, MD, MPH, JD, said in a statement. “This

TRUCKEE trial: Faricimab ‘has helped a lot of people’ with wet AMD in real world

NEW ORLEANS — Real-world results of the TRUCKEE study at 4.5 years showed that faricimab was “safe, efficacious and improved anatomy” in patients with wet age-related macular degeneration.
In this video from the American Academy of Ophthalmology meeting, Carl J. Danzig, MD, of Fort Lauderdale Eye Institute, patients with wet AMD who switched from anti-VEGF therapy to Vabysmo (faricimab, Genentech) were able to extend the injection interval by nearly 2 weeks after nine injections, whereas treatment-naive patients were able to achieve injection intervals of 10 to 11 weeks after approximately 10

FDA OKs Talzenna, enzalutamide combo for prostate cancer

The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen pathway modulation-naive or -sensitive prostate cancer with homologous recombination repair gene mutations.
“This approval represents a critical advancement for patients with newly diagnosed metastatic prostate cancer with HRR gene mutations, who face a more aggressive disease, worse prognosis, and limited treatment options,” Neeraj Agarwal, MD, FASCO, co-director of the prostate cancer program at Harvard Cancer Consortium, medical oncologist at Dana-Farber Cancer Institute